Abstract:Background With the popularization of low-dose spiral computed tomography (CT), an increasing number of stage I lung cancers have been discovered. Although most of the patients with stage I lung adenocarcinoma have a favorable prognosis, some patients still have a poor prognosis of recurrence and metastasis after surgery. The immune system has been shown to play an important role in the development of cancer. Our aim is to identify a reliable prognostic signature of immune-related genes that can predict prognosis and help in the individualized management of patients with stage I lung adenocarcinoma. Methods In this study, the immune-related genes were first extracted by the ImmPort database. Subsequently, these genes were screened using univariate Cox regression and LASSO regression to identify prognostic signatures, followed by construction of a prognostic model using multivariate Cox regression. A nomogram was developed to predict the prognosis of stage I lung adenocarcinoma and to evaluate the nomogram differentiation and accuracy using the receiver operating characteristic curve, clinical decision analysis and calibration curve. The model was validated in two independent data sets: GSE31210 and GSE30219. Then, patients were stratified based on median risk scores, and differential expression genes between the two groups were analyzed. Finally, the enrichment analysis and the immune infiltration analysis were performed. Results In this study, we found 29 immune-related genes and developed a gene signature with poor prognosis in stage I lung adenocarcinoma. Our model was validated using two independent datasets and demonstrated robust performance with good AUC values and clinical utility. Enrichment analysis indicated that immune-related genes signature has multifaceted effects on stage I lung adenocarcinoma, especially related to tumor development, proliferation, and metastasis. Patients in the high-risk group had higher tumor purity, lower matrix, estimated and immune scores, suggesting a potentially immunosuppressive tumor microenvironment. Conclusion This study constructed a gene signature related to immunity in stage I lung adenocarcinoma and analyzed its impact on tumor development and its relationship with the tumor microenvironment. The findings can contribute to a more precise survival risk stratification and personalized clinical management for stage I lung adenocarcinoma patients. Furthermore, we provide related opinions for future immune-related research by elucidating potential underlying mechanisms.

Analysis of the tumor immune environment identifies an immune gene set-based prognostic signature in non-small cell lung cancer

Identification of Immune-Related Gene Signature Model for Predicting Lung Cancer Survival and Response to Immunotherapy

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

A tumor microenvironment gene set-Based prognostic signature for non-small-cell lung cancer

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Identification of a Immune-Related Genes Signature for Survival Prediction in Stage I Lung Adenocarcinoma

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma

Identification of Inflammatory Response-Related Gene Signature Associated With Immune Status and Prognosis of Lung Adenocarcinoma

Establishment of a prognostic signature for patients with advanced lung squamous cell carcinoma based on tumor-infiltrating immune cells

Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis

Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma

Identification of Prognostic Immune-Related Signature Predicting the Overall Survival for Colorectal Cancer

A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis

A New Immune Signature for Survival Prediction and Immune Checkpoint Molecules in Non-Small Cell Lung Cancer

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma

Development and validation of an immune-related gene signature for prognosis in Lung adenocarcinoma.

Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer

A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma